Upgrade to SI Premium - Free Trial

Beam Therapeutics Inc. (BEAM)

27.48 +0.23 (0.84%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26 *Est.)

Latest Headlines

Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan August 5, 2026 8:11 AM - StreetInsider Form 10-Q Beam Therapeutics Inc. For: Jun 30 August 4, 2026 7:14 AM - SEC Filing Beam, Inc. (BEAM) Misses Q2 EPS by 8c August 4, 2026 7:14 AM - StreetInsider Form 8-K Beam Therapeutics Inc. For: Aug 04 August 4, 2026 7:09 AM - SEC Filing Beam Therapeutics posts Q2 loss, doses first patient in BEAM-302 trial August 4, 2026 7:00 AM - StreetInsider Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) August 4, 2026 7:00 AM - StreetInsider Form 4 Beam Therapeutics Inc. For: Jul 27 Filed by: Simon Amy July 29, 2026 4:05 PM - SEC Filing Form 144 Beam Therapeutics Inc. Filed by: Simon Amy July 27, 2026 4:05 PM - SEC Filing Beam Therapeutics to present BEAM-302 trial data at ERS 2026 July 23, 2026 7:00 AM - StreetInsider Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres July 23, 2026 7:00 AM - StreetInsider TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential' July 8, 2026 12:30 PM - StreetInsider BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff July 8, 2026 11:32 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) July 7, 2026 7:03 AM - StreetInsider Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy July 2, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M. July 1, 2026 4:05 PM - SEC Filing Form 144 Beam Therapeutics Inc. Filed by: Evans John M. June 30, 2026 4:19 PM - SEC Filing Form 144 Beam Therapeutics Inc. Filed by: Evans John M. June 29, 2026 4:15 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC June 29, 2026 2:17 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 17 Filed by: Ciaramella Giuseppe June 22, 2026 4:05 PM - SEC Filing FDA clears Beam Therapeutics IND for PKU gene editing therapy June 18, 2026 7:00 AM - StreetInsider Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration June 18, 2026 7:00 AM - StreetInsider Form 8-K Beam Therapeutics Inc. For: Jun 03 June 8, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: MARAGANORE JOHN June 5, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Shaw Christi June 5, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Walsh Kathleen E June 5, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Guindo Chirfi June 5, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: COOPER GRAHAM K June 5, 2026 4:05 PM - SEC Filing Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Fishman Mark June 5, 2026 4:05 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) May 21, 2026 6:39 AM - StreetInsider Beam Therapeutics presents BEAM-302 data at conference May 18, 2026 4:00 PM - StreetInsider Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference May 18, 2026 4:00 PM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) May 14, 2026 6:48 AM - StreetInsider Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 May 13, 2026 11:49 AM - PR NewsWire Beam Therapeutics Inc (BEAM) PT Lowered to $39 at Bernstein SocGen Group May 13, 2026 7:15 AM - StreetInsider Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference May 13, 2026 7:00 AM - Globe NewsWire Beam Therapeutics to present sickle cell therapy data at EHA2026 May 12, 2026 9:30 AM - StreetInsider Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA20 May 12, 2026 9:30 AM - Globe NewsWire Full Article List